Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 17/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27435858 | 0.90 | CYP4F2 (0.36) | CYP2D6SLC6A2SLC6A4SLC6A3CYP4F2 | |
| SCHEMBL27427642 | 0.86 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL29156971 | 0.85 | CYP4F2 (0.38) | CYP2D6SLC6A2SLC6A4SLC6A3CYP4F2 | |
| SCHEMBL4339942 | 0.83 | SLC6A2 (0.36) | CYP2D6SLC6A2SLC6A4SLC6A3CYP4F2 | |
| SCHEMBL2298802 | 0.83 | SLC6A2 (0.36) | CYP2D6SLC6A2SLC6A4SLC6A3CYP4F2 | |
| SCHEMBL18044818 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL25273742 | 0.78 | CYP4F2 (0.37) | CYP2D6SLC6A2SLC6A4SLC6A3CYP4F2 | |
| SCHEMBL7470646 | 0.78 | CYP2D6 (0.36) | CYP2D6SLC6A2SLC6A4SLC6A3CYP4F2 | |
| Toluene SCHEMBL27486527 | 0.78 | OPRM1 (0.44) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL782051 | 0.78 | CYP4F2 (0.38) | CYP4F2CYP4A11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | disclosed |
| CN-1816332-A | 3-aminomethyl-pyrrolidines as N-type calcium channel blockers | NEUROMED TECH INC (CA) | 2006-08-09 | — | — | CN | disclosed |
| EP-1633343-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Technologies, Inc. (CA) | 2006-03-15 | — | — | EP | disclosed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004105750-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | CYP2D6 3363/4885SLC6A2 723/4885SLC6A4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.